Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

drug-repurposing

7 stories tagged "drug-repurposing"

Cancer

To Keep Cancer-Fighting Cells Alive, a Sloan Kettering Lab Wants Them to Fight Less Hard

Memorial Sloan Kettering researchers say throttling exhausted T cells with a drug class already used against melanoma may keep them alive longer. So far the evidence comes only from lab and animal models.

Cancer

A Generic Vitamin D Drug Quadrupled Chemo Responses in a Small Pancreatic Cancer Trial, and Its Phase 2 Never Ran

Forty-two percent of patients on paricalcitol plus chemo saw their tumors shrink, versus 9 percent on placebo, in a 36-person safety trial. The randomized phase 2 meant to follow it never ran.

Drugs & FDA

No FDA-Approved Drug Stops Preterm Labor: a Vanderbilt Screen of All 1,191 Approved Drugs Landed on an Asthma Steroid

Every drug used to halt preterm contractions is borrowed off-label; the FDA has never approved one for the job. A Vanderbilt team screened all 1,191 approved drugs and landed on an asthma steroid.

Autoimmune & Inflammation

A Fat 'Brake' Eased Pain in 49 Men but Barely Touched the Swelling

UCL researchers gave 49 healthy men a drug GlaxoSmithKline shelved after early trials. Pain resolved faster and a class of immune cells shrank, but the heat, redness, and swelling showed no significant change.

Cancer

UC Irvine's 'Framework' for Safer CAR-T Is a Hypothesis Essay, Not a Study

The senior author consults for Kite Pharma, whose Yescarta accounted for all 6 grade-5 neurotoxicity deaths in the cited review's real-world data, the exact harm the paper proposes to treat.

Drugs & FDA

The FDA Pulled Infigratinib as a Cancer Drug in 2024. It Just Passed Phase 3 in Children With Dwarfism.

The FDA pulled infigratinib as a failed cancer drug in 2024. Now its maker says the same pill grows children with dwarfism faster, on a surrogate no one has yet shown reaches adulthood.

Cancer

Fibrolamellar Carcinoma Hides Immune Cells in Scar Tissue. A Drug Approved in 2008 Pulled Them Back Out.

Fibrolamellar carcinoma mostly kills young adults, and checkpoint immunotherapy bounces off it. Researchers found the tumor herds T cells into fibrous bands, and a drug shelved for stem-cell work since 2008 freed them in patient tissue. No human trial has started.